Company intelligence / Profile preview

江西亿友药业

Fuzhou, Jiangxi, China

Ownership: Private
Development stage: Other

Overview

Jiangxi Yiyou Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Fuzhou, Jiangxi, China, dedicated to the development of innovative small molecule therapeutics. The company primarily focuses on high-prevalence diseases in China, including chronic hepatitis B and various cancers. Its lead asset, YI-101, is a first-in-class inhibitor of the Hepatitis B virus X protein (HBx), designed to achieve a functional cure for HBV. Yiyou Pharmaceutical maintains an integrated business model encompassing drug discovery, clinical development, and GMP-compliant manufacturing facilities.

Therapeutic areas: Infectious DiseasesOncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on 江西亿友药业.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 江西亿友药业.

Explore the full profile